Recent Patents on CNS Drug Discovery

Vincenzo Di Marzo
Istituto di Chimica Biomolecolare (I.C.B.)
Consiglio Nazionale delle Ricerche (C.N.R.)
Via Campi Flegrei 34
Pozzuoli, Napoli 80078
Italy

Back

The Role of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis. Where are we Now?

Author(s): Vasileios T. Papaliagkas

Affiliation: Third Department of Neurology, G Papanikolaou Hospital, Exohi Thessaloniki, Greece.

Keywords: Alzheimer’s disease (AD), Abeta42, cytochrome c, secretases, Tau.

Abstract:

Alzheimer’s disease (AD) is a rapidly growing disease that is estimated to affect about 36 million people worldwide, therefore there is an immediate need for its’ early diagnosis and treatment. A number of research studies are performed on possible accurate and reliable diagnostic biomarkers of AD. This review study provides an update on the cerebrospinal fluid (CSF) proteins that are being currently used in clinical practice and studied as biomarkers for early AD diagnosis and their future prospects, as well as relevant patents.

Reprint ePrint Rights & PermissionsPrintExport

Article Details

VOLUME: 8
ISSUE: 1
Page: [70 - 78]
Pages: 9
DOI: 10.2174/1574889811308010006